eePASSIGE System Wins Major Biotechnology Award by End of 2024?

First Major Pharmaceutical Company to Partner on eePASSIGE?

First Clinical Application of eePASSIGE System?

Publication Demonstrating Therapeutic Levels of eePASSIGE in Human Cells by Q3 2024?

Human Clinical Trials for eePASSIGE System by Mid-2024?

FDA Approval of eePASSIGE System by End of 2024?

Will FDA approve prime editing treatment for cystic fibrosis by end of 2024?

Prime editing approach for CFTR F508del mutation to enter clinical trials by Dec 31, 2024?

Peer-reviewed study confirms efficacy of prime editing approach in animal models by June 30, 2025?

Major pharmaceutical company to announce partnership for prime editing treatment by Dec 31, 2024?

First clinical trial phase reached by prime editing approach for CFTR F508del mutation by Dec 31, 2025?

First regulatory body to approve prime editing approach for CFTR F508del mutation by Dec 31, 2026?

Primary outcome measure in first clinical trial of prime editing approach for CFTR F508del mutation by Dec 31, 2025?

How many patients will be enrolled in the first human clinical trial for the new lipid nanoparticle-based treatment for cystic fibrosis by end of 2024?

Which country will first approve prime editing treatment for cystic fibrosis by end of 2024?

Which pharmaceutical company will first license prime editing treatment for cystic fibrosis by mid-2025?

Will successful human clinical trial results for prime editing treatment of CFTR F508del mutation be published by mid-2025?

Will human clinical trials for new lipid nanoparticle-based treatment for cystic fibrosis start by end of 2024?